

# CÁNCER INFANTIL

## **Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study.**

Kovács G, Wachtel A, Basharova E, Spinelli T, Nicolas P, Kabickova E.

Future Oncol. 2017 Aug;13(19):1685-1698.

### Abstract

**AIM:** To investigate across multiple cycles the efficacy and safety of palonosetron in the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients receiving highly or moderately emetogenic chemotherapy (HEC/MEC).

**PATIENTS & METHODS:** Patients were randomly assigned to 10, 20 µg/kg palonosetron or 3 × 150 µg/kg ondansetron for up to four cycles of HEC/MEC.

**RESULTS:** In all on-study chemotherapy cycles, complete response rates were higher in patients in the 20 µg/kg palonosetron group than the ondansetron group. Treatment-emergent adverse events were comparable between the palonosetron 20 µg/kg and ondansetron groups.

**CONCLUSION:** Over four cycles of HEC/MEC, 20 µg/kg palonosetron was an efficacious and safe treatment for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients.